

Cancer Association of South Africa (CANSA)



Fact Sheet on Insulinoma

Introduction

The pancreas is about 15 centimetres long and lies across the back of the abdomen, behind the stomach. The head of the pancreas is on the right side of the abdomen and is connected to the duodenum (the first section of the small intestine) through a small tube called the pancreatic duct. The narrow end of the pancreas, called the tail, extends to the left side of the body.

The pancreas is made up of exocrine cells and endocrine cells. These cells have different functions.


[Picture Credit: Pancreas]

Most of the cells in the pancreas are exocrine cells. Exocrine cells make and release pancreatic juice. The juice travels through the pancreatic duct into the duodenum. Enzymes in the pancreatic juice help digest fat, carbohydrates and protein in food.

A small number of the cells in the pancreas are endocrine cells. They are arranged in clusters called islets, or islets of Langerhans. The islets make, and release, insulin and glucagon into the blood. These hormones help control the level of sugar, or glucose, in the blood.

Insulin lowers the amount of sugar in the blood when the blood sugar is high. It also stimulates the liver, muscles and fatty tissues to absorb and store the extra blood sugar.

Glucagon increases the amount of sugar in the blood when the blood sugar is low. It stimulates the liver and other body tissues to release stored sugar into the blood.



Pancreatic Tissue

Insulinoma

An insulinoma is a tumour of the pancreas that is derived from beta cells and secretes insulin. It is a rare form of a neuroendocrine tumour. Most insulinomas are benign in that they grow exclusively at their origin within the pancreas, but a minority metastasise. Insulinomas are one of the functional PanNET group ("functional" because it increases production of insulin; "PanNET" as an abbreviation of pancreatic neuroendocrine tumour).

Beta cells secrete insulin in response to increases in blood glucose. The resulting increase in insulin acts to lower blood glucose back to normal levels at which point further secretion of insulin is stopped. In contrast, the secretion of insulin by insulinomas is not properly regulated by glucose and the tumours will continue to secrete insulin causing glucose levels to fall further than normal.

As a result patients present symptoms of low blood glucose (hypoglycaemia), which are improved by eating. The diagnosis of an insulinoma is usually made biochemically with low blood glucose, elevated insulin, proinsulin and C-peptide levels and confirmed by localising the tumour with medical imaging or angiography. The definitive treatment is surgery.

Incidence of Insulinoma in South Africa

The National Cancer Registry (2014) does not provide any information regarding the incidence of Insulinoma.

According to the National Cancer Registry (2014) the following number of pancreatic cancer cases was histologically diagnosed in South Africa during 2014:

Group - Males 2014	Actual No of Cases	Estimated Lifetime Risk	Percentage of All Cancers
All males	167	1:869	0,45%
Asian males	9	1:349	1,00%
Black males	46	1:2 505	0,42%
Coloured males	27	1:580	0,64%
White males	85	1:358	0,41%

Group - Females 2014	Actual No of Cases	Estimated Lifetime Risk	Percentage of All Cancers
All females	175	1:1 125	0,46%
Asian females	3	1:1 890	0,26%
Black females	63	1:2 297	0,39%
Coloured females	21	1:760	0,50%
White females	89	1:431	0,54%

The frequency of histologically diagnosed cases of pancreatic cancer in South Africa for 2014 was as follows (National Cancer Registry, 2014):

Group - Males 2014	0 – 19 Years	20 – 29 Years	30 – 39 Years	40 – 49 Years	50 – 59 Years	60 – 69 Years	70 – 79 Years	80+ Years
All males	0	0	2	22	47	57	29	9
Asian males	0	0	0	1	0	4	4	0
Black males	0	0	2	13	13	13	1	2
Coloured males	0	0	0	2	6	13	3	2
White males	0	0	1	3	28	24	24	2

Group - Females 2014	0 – 19 Years	20 – 29 Years	30 – 39 Years	40 – 49 Years	50 – 59 Years	60 – 69 Years	70 – 79 Years	80+ Years
All females	1	1	5	18	39	551	39	19
Asian females	0	0	0	0	0	0	0	0
Black females	1	1	4	8	16	17	10	2
Coloured females	0	0	1	2	8	6	3	0
White females	0	0	0	7	14	25	23	17

N.B. In the event that the totals in any of the above tables do not tally, this may be the result of uncertainties as to the age, race or sex of the individual. The totals for 'all males' and 'all females', however, always reflect the correct totals.

Signs and symptoms of Insulinoma

- Insulinomas are characterised clinically by the Whipple triad, as follows:
 - Presence of symptoms of hypoglycaemia [low blood sugar] (about 85% of patients)
 - Documented low blood sugar at the time of symptoms
 - Reversal of symptoms by glucose administration
- About 85% of patients with insulinoma present with one of the following symptoms of hypoglycaemia:
 - Diplopia (double vision)
 - Blurred vision
 - Palpitations
 - Weakness
- Hypoglycaemia can also result in the following:
 - Confusion
 - Abnormal behaviour
 - Unconsciousness
 - Amnesia (memory loss)
- Clinical Picture
 - Adrenergic symptoms (from hypoglycaemia-related adrenalin release): Weakness, sweating, tachycardia (rapid pulse), palpitations, and hunger
 - Seizures
 - About 85% of patients present with symptoms of hypoglycaemia (low blood sugar) that include diplopia, blurred vision, palpitations, or weakness
 - Other symptoms include confusion, abnormal behaviour, unconsciousness, or amnesia
 - About 12% of patients have grand mal (major) seizures
 - Adrenergic symptoms (hypoglycaemia causes adrenalin release) include weakness, sweating, tachycardia (rapid pulse rate), palpitations, and hunger

- Symptoms may be present from 1 week to as long as several decades prior to the diagnosis (1 month to 30 years, median 24 months, as found in a large series of 59 patients). Symptoms may occur most frequently at night or in the early morning hours
- Hypoglycaemia usually occurs several hours after a meal
- In severe cases, symptoms may develop in the postprandial period (occurring after a meal). Symptoms can be aggravated by exercise, alcohol, hypocaloric diet, and treatment with sulfonylureas
- Weight gain occurs in 20-40% of patients. Because of hyperinsulinism, many patients may be overweight

Diagnosis of Insulinoma

The biochemical diagnosis is established in 95% of patients during prolonged fasting (up to 72 hours) when the following parameters are found:

- Serum insulin levels of 10 $\mu\text{U}/\text{mL}$ or more (normal $<6 \mu\text{U}/\text{mL}$)
- Glucose levels of less than 40 mg/dL
- C-peptide levels exceeding 2.5 ng/mL (normal $<2 \text{ ng}/\text{mL}$)
- Proinsulin levels $\geq 22 \text{ pmol}/\text{L}$, or greater than 25% (or up to 90%) that of immunoreactive insulin
- Screening for sulfonylurea negative

Câmara-de-Souza, A.B., Toyoshima, M.T.K., Giannella, M.L., Freire, D.S., Camacho, C.P., Lourenço, D.M. Jr., Rocha, M.S., Bacchella, T., Jureidini, R., Machado, M.C.C., Almeida, M.Q. & Pereira, M.A.A. 2018.

BACKGROUND/OBJECTIVES: Insulinoma is a rare pancreatic tumor and, usually, a benign disease but can be a malignant one and, sometimes, a highly aggressive disease. The aim of this study was to determine differences between benign and malignant tumors.

METHODS: Retrospective study of 103 patients with insulinoma treated in a tertiary center. It was analyzed demographic, clinical, laboratory, localization and histologic analysis of tumor and follow up data of subjects in order to identify differences between individuals benign and malignant disease.

RESULTS: Almost all patients (87%) had a benign tumor and survival rates of 100% following pancreatic tumor surgery. Those with malignant tumors (13%) have a poor prognosis, 77% insulinoma-related deaths over a period of 1-300 months after the diagnosis with a survival rate of 24% in five years. The following factors are associated with an increased risk of malignant disease: duration of symptoms < 24 months, fasting time for the occurrence of hypoglycemia < 8 h, blood plasma insulin concentration $\geq 28 \mu\text{U}/\text{mL}$ and C-peptide $\geq 4.0 \text{ ng}/\text{mL}$ at the glycemic nadir and tumor size $\geq 2.5 \text{ cm}$.

CONCLUSIONS: Our data help to base the literature about these tumors, reinforcing that although insulinoma is usually a single benign and surgically treated neoplasia, the malignant one is difficult to treat. We highlight the data that help predict a malignancy behavior of tumor and suggest a long follow up after diagnosis in these cases.

Treatment of Insulinoma

The main treatment for insulinomas is surgery. This cures most insulinomas. But surgery is not always possible. Some cancerous insulinomas have already spread when they are diagnosed. If one cannot have surgery one will have drug treatment to control blood sugar levels and other symptoms.

The treatment depends on:

- Whether one has one or more tumours
- Whether the tumour is benign or malignant
- Whether the tumour has spread to other parts of the body
- Where in the pancreas the tumours are
- General health of the patient
- Whether the patient has a familial cancer syndrome

Other treatments may include:

- Treatment to control symptoms
- Chemotherapy

Surgery - the type of surgery the patient has will depend on:

- Whether he/she has one or more tumours
- Where in the pancreas the tumour is
- The size of the tumour

Treating symptoms of insulinoma - some cancerous (malignant) insulinomas are diagnosed when they are already advanced. And some come back after treatment. The most common place for malignant insulinoma to spread to is the liver.

Radiofrequency ablation – This procedure uses heat made by radio waves to kill cancer cells.

Cryotherapy – This procedure uses a cold probe to destroy cells and tissue by freezing.

Transcatheter arterial chemoembolisation (it is also sometimes referred to as transarterial chemoembolisation or TACE) - is a minimally invasive procedure performed in interventional radiology to restrict a tumour's blood supply. Small embolic particles coated with chemotherapeutic agents are injected selectively into an artery directly supplying a tumour. The substance may also be a gel or tiny plastic beads and helps to keep the chemotherapy around the tumour.

Selective internal radiation therapy (SIRT) - is a form of radiation therapy used in interventional radiology to treat cancer. It is generally for selected patients with unresectable cancers, those that cannot be treated surgically, especially hepatic cell carcinoma or metastasis to the liver. SIRT - is when microscopic beads that are coated with a radioactive substance called Yttrium-90 and is a type of targeted radiotherapy.

Drugs and diet to control blood sugar - the symptoms of an insulinoma can be difficult to cope with. To help to control blood sugar, the patient may need to have a high glucose diet. Being aware of the symptoms of a low blood sugar will help the patient correct it quickly by eating something that contains glucose.

Chemotherapy - may also help to control symptoms of a malignant insulinoma that cannot be removed with surgery. The drugs used may include doxorubicin and streptozocin. (Cancer Research UK).

Matej, A., Bujwid, H. & Wroński, J. 2016.

“Insulinoma is the most common neuroendocrine tumor of the pancreas. Surgical management of insulinomas is considered to be the only curative method. However, effective glycemic control preoperatively and in unresectable insulinomas remains a significant issue. Hyperinsulinism, occurring as a result of the hormone-secreting tumor, leads to life-threatening hypoglycemia episodes which require urgent medical treatment. This article discusses current management of hypoglycemia in insulinomapatients, including: education and lifestyle modifications, pharmacotherapy (diazoxide, somatostatin analogs, mTOR inhibitor - everolimus), cytoreductive methods and continuous glucose monitoring systems.”

About Clinical Trials

Clinical trials are research studies that involve people. They are conducted under controlled conditions. Only about 10% of all drugs started in human clinical trials become an approved drug.

Clinical trials include:

- Trials to test effectiveness of new treatments
- Trials to test new ways of using current treatments
- Tests new interventions that may lower the risk of developing certain types of cancers
- Tests to find new ways of screening for cancer

The South African National Clinical Trials Register provides the public with updated information on clinical trials on human participants being conducted in South Africa. The Register provides information on the purpose of the clinical trial; who can participate, where the trial is located, and contact details.

For additional information, please visit: www.sanctr.gov.za/

Medical Disclaimer

This Fact Sheet is intended to provide general information only and, as such, should not be considered as a substitute for advice, medically or otherwise, covering any specific condition or situation. Readers of this document should seek appropriate medical advice prior to taking or refraining from taking any action resulting from the contents of this Fact Sheet. As far as permissible by South African law, the Cancer Association of South Africa (CASNA) accepts no responsibility or liability to any person (or his/her dependants/estate/heirs) as a result of using any information contained in this Fact Sheet.

The Cancer Association of South Africa (CANSAs) has taken every precaution in preparing this Fact Sheet. Neither CANSAs, nor any contributor(s) to this Fact Sheet shall be held responsible for any action (or the lack of any action) taken by any person or organisation wherever they shall be based, as a result, directly or indirectly, of information contained in, or accessed through, this Fact Sheet.



Sources and References Consulted or Utilised

Câmara-de-Souza, A.B., Toyoshima, M.T.K., Giannella, M.L., Freire, D.S., Camacho, C.P., Lourenço, D.M. Jr., Rocha, M.S., Bacchella, T., Jureidini, R., Machado, M.C.C., Almeida, M.Q. & Pereira, M.A.A. 2018. Insulinoma: a retrospective study analysing the differences between benign and malignant tumors. *Pancreatology*. 2018 Apr;18(3):298-303. doi: 10.1016/j.pan.2018.01.009. Epub 2018 Feb 1.

Canadian Cancer Society

<http://www.cancer.ca/en/cancer-information/cancer-type/pancreatic/anatomy-and-physiology/?region=on>

Cancer Research UK

<http://www.cancerresearchuk.org/about-cancer/cancers-in-general/cancer-questions/insulinomas>

eMedicine

<http://emedicine.medscape.com/article/283039-workup>

Matej, A., Bujwid, H. & Wroński, J. 2016. Glycemic control in patients with insulinoma. *Ormones (Athens)*. 2016 Oct;15(4):489-499. doi: 10.14310/horm.2002.1706.

Medscape

<http://emedicine.medscape.com/article/283039-clinical>

<http://emedicine.medscape.com/article/283039-overview>

National Cancer Institute

<http://www.cancer.gov/cancertopics/factsheet/clinicaltrials/clinical-trials>

Pancreas

https://en.wikipedia.org/wiki/Pancreas#/media/File:Blausen_0701_PancreaticTissue.png

WebMD

<http://www.webmd.com/digestive-disorders/picture-of-the-pancreas>

Wikipedia

<https://en.wikipedia.org/wiki/Insulinoma>